New insider activity at Medpace Holdings ( (MEDP) ) has taken place on November 26, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
In a significant move, CEO August J. Troendle has offloaded 101,417 shares of Medpace Holdings, amounting to a staggering $61,967,338. Meanwhile, Executive Vice President of Operations, Susan E. Burwig, has also sold 20,000 shares, bringing in $12,183,000. These transactions highlight notable insider activity within the company.
Recent Updates on MEDP stock
Recent developments surrounding Medpace Holdings Inc. have been marked by several significant clinical collaborations and studies, which could influence its stock performance. BMO Capital initiated coverage with a Market Perform rating, citing a full valuation amidst a “tepid” biotech funding environment and potential macroeconomic volatility. Medpace’s ongoing clinical studies include collaborations with AVM Biotechnology on the OPAL Study for lymphoid malignancies and a promising ARDS study, both of which could enhance investor confidence if successful. Additionally, partnerships with Telix Pharmaceuticals and Radiopharm Theranostics on advanced cancer treatments highlight Medpace’s strategic positioning in oncology, potentially driving positive sentiment in the competitive healthcare sector. These developments underscore Medpace’s active role in advancing innovative therapies, which may impact its stock valuation as results emerge.
Spark’s Take on MEDP Stock
According to Spark, TipRanks’ AI Analyst, MEDP is a Outperform.
Medpace Holdings demonstrates strong financial performance and positive earnings call sentiment, which are the most significant factors driving the score. Technical analysis indicates strong momentum but also suggests caution due to overbought conditions. The high P/E ratio impacts the valuation score, reflecting potential overvaluation concerns.
To see Spark’s full report on MEDP stock, click here.
More about Medpace Holdings
YTD Price Performance: 82.77%
Average Trading Volume: 314,378
Technical Sentiment Signal: Buy
Current Market Cap: $17.23B